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Abstract
Aim This subgroup analysis of a prospective multicentre
cohort study aims to compare postoperative morbidity
between transanal total mesorectal excision (TaTME)
and laparoscopic total mesorectal excision (LaTME).
Method The study was designed as a subgroup analysis
of a prospective multicentre cohort study. Patients
undergoing TaTME or LaTME for rectal cancer were
selected. All patients were followed up until the first
visit to the outpatient clinic after hospital discharge.
Postoperative complications were classified according to
the Clavien–Dindo classification and the comprehensive
complication index (CCI). Propensity score matching
was performed.
Results In total, 220 patients were selected from the
overall prospective multicentre cohort study. After
propensity score matching, 48 patients from each group
were compared. The median tumour height for TaTME
was 10.0 cm (6.0–10.8) and for LaTME was 9.5 cm
(7.0–12.0) (P = 0.459). The duration of surgery and
anaesthesia were both significantly longer for TaTME
(221 vs 180 min, P < 0.001, and 264 vs 217 min,
P < 0.001). TaTME was not converted to laparotomy
whilst surgery in five patients undergoing LaTME was
converted to laparotomy (0.0% vs 10.4%, P = 0.056).
No statistically significant differences were observed for
Clavien–Dindo classification, CCI, readmissions, reoper-
ations and mortality.
Conclusion The study showed that TaTME is a safe
and feasible approach for rectal cancer resection. This
new technique obtained similar postoperative morbidity
to LaTME.
Keywords rectal cancer, minimal invasive surgery,
laparoscopic, transanal
What does this paper add to the literature?
Transanal total mesorectal excision (TaTME) is an
emerging surgical technique for rectal cancer resection.
This study is the first to provide results of a prospective
multicentre cohort study comparing TaTME and
laparoscopic total mesorectal excision. TaTME is a safe
and feasible approach for rectal cancer resection.
TaTME obtained similar postoperative morbidity and
required fewer conversions.
Introduction
Total mesorectal excision (TME) is the gold standard
for rectal resection. This surgical technique, involving
resection of the fatty envelope surrounding the rectum,
has substantially contributed to local control and sur-
vival of rectal cancer [1,2].
Minimally invasive techniques have been intro-
duced for rectal surgery. Several randomized
controlled trials have shown that oncological out-
comes are comparable for open and laparoscopic sur-
gery for rectal cancer. The COREAN trial has shown
short-term benefits for laparoscopic surgery compared
to open surgery and an equivalent quality of onco-
logical resection [3]. In the long term, disease-free
survival was similar for the two techniques [4]. In
addition, The COLOR-II trial has confirmed that
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laparoscopic and open surgery for rectal cancer pro-
vide similar long-term outcomes [5].
Recently, it has been shown that age above 65 years,
a body mass index (BMI) greater than 25 and tumour
location close to the anal verge are risk factors for the
conversion from laparoscopic to open surgery [6]. In
addition, factors such as a narrow pelvis or limited views
of the distal rectum make the laparoscopic approach dif-
ficult. These considerations emphasize the need for a
new minimally invasive technique that overcomes the
limitations of laparoscopy.
Transanal total mesorectal excision (TaTME) may be
the solution. Since its introduction in 2010, TaTME
has been shown to be a feasible and safe technique for
rectal cancer resections and has subsequently achieved
widespread acceptance [7,8]. Nevertheless, to date,
most evidence has been obtained from cohort studies
with small sample sizes and retrospective design [9–13].
Therefore, this study is important because it is the first
to provide results of a prospective multicentre cohort
study. The aim of the study was to compare postopera-
tive morbidity between TaTME and laparoscopic total
mesorectal excision (LaTME).
Method
The study was designed as a subgroup analysis of a
prospective multicentre cohort study, the APPEAL-II
study. Ten hospitals in the Netherlands and Belgium par-
ticipated. The study was approved by the medical ethics
committee of the Erasmus University Medical Center in
the Netherlands and of the University Hospital Leuven in
Belgium. We also obtained approval from local ethics
committees of the participating hospitals. This prospec-
tive cohort was established between August 2015 and
October 2017. Patients aged 18 years and older who
underwent partial mesorectal excision (PME) or TME
with construction of a colorectal or coloanal anastomosis
were eligible for inclusion. We excluded pregnant women
and patients who underwent emergency procedures. All
patients received a pelvic drain during surgery that was
kept in place for at least the first three postoperative days.
Drain fluid was obtained for further analysis according to
the study protocol (https://doi.org/10.1186/isrc
tn84052649). Follow-up, for the purposes of this study,
was completed at the first visit at the outpatient clinic
after hospital discharge. Informed consent was obtained
from all patients. For this subgroup analysis, we selected
patients who underwent TaTME or LaTME for rectal
cancer. Patient selection for TaTME or LaTME was at
discretion of the surgeon.
Baseline characteristics [age, gender, BMI, smoking,
alcohol abuse (> 14 units per week), American Society of
Anesthesiologists (ASA) score, tumour location, neoadju-
vant radiotherapy, neoadjuvant chemotherapy, patholog-
ical TNM staging] and surgical characteristics [duration
of surgery, duration of anaesthesia, conversion, construc-
tion of anastomosis, configuration of anastomosis, divert-
ing ileostomy, circumferential resection margin (CRM),
distal resection margin (DRM)] were prospectively regis-
tered. CRM was considered positive when the margin
was < 1 mm and for the DRM this was < 1 cm [14].
Outcome measures
The outcome measures of this analysis were postoperative
complications, readmissions, reoperations, conversions
and mortality. Stoma reversals were not considered as
reoperations unless they were due to stoma complica-
tions. Anastomotic leakage was defined as clinically mani-
fest insufficiency of the anastomosis leading to a clinical
state requiring re-intervention (i.e. Grade B/C) [15].
Anastomotic leakage was confirmed by endoscopy, CT
scan and/or contrast enema or reoperation. Re-interven-
tion for anastomotic leakage consisted of therapeutic
antibiotics, (endoscopic) drainage or a surgical re-inter-
vention. Presacral abscesses were classified as anastomotic
leakage if extravasation of the colonic contrast was visible
on radiological imaging. Fistulas attached to the anasto-
mosis on CT scan were also classified as anastomotic
leakage. Postoperative complications were classified
according to the Clavien–Dindo classification system and
Grade II or higher was considered to be a severe compli-
cation [16,17]. In addition, the comprehensive complica-
tion index (CCI) for every patient was calculated using
www.assessurgery.com [18].
Statistical analysis
Continuous variables were described as median  in-
terquartile range and compared with the Mann–Whitney
U test. Categorical variables were described as percent-
ages and compared using the chi-squared test or Fisher’s
exact test when needed. Patients were matched based on
the propensity score derived from a logistic regression
model with approach as dependent covariate and baseline
characteristics with P value < 0.1 as independent covari-
ates. In addition, a multivariate penalized logistic/linear
regression model was built to investigate the adjusted
association between the surgical approach and the
outcome measures adjusted for the aforementioned risk
factors in the unmatched dataset (age, gender, BMI,
tumour location, pathological tumour stage, neoadjuvant
radiotherapy, neoadjuvant chemotherapy, diverting
ileostomy, approach). All clinically relevant variables were
added to the model. Statistical significance was defined as
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P value < 0.050. All analyses were performed using SPSS
software 21.0 (IBM, Armonk, New York, USA) or
(R software, http://www.r-project.org).
Results
This prospective cohort study of patients undergoing
PME or TME included 301 patients. For this analysis, we
excluded 74 patients who underwent PME or who had
an open approach and seven patients who were operated
upon for reasons other than rectal cancer. In total, 220
patients were selected (Fig. 1). The median follow-up
was 27.0 days (interquartile range 19.0–34.0 days).
Table 1 shows prematching baseline characteristics of
the overall study population of 220 patients. Age,
tumour location, pathological T staging and neoadju-
vant chemotherapy were used to calculate the propen-
sity score. After matching for propensity score, 96
patients were eligible for analysis.
Table 2 shows postmatching baseline characteristics
of 48 patients undergoing TaTME and 48 patients
undergoing LaTME. Patients undergoing LaTME
received neoadjuvant radiotherapy more often (43.8% vs
64.6%, P = 0.041). The other baseline characteristics
were not statistically significantly different for TaTME
and LaTME. Duration of surgery and anaesthesia were
both significantly longer for TaTME (221 vs 180 min,
P < 0.001; 264 vs 217 min, P < 0.001). TaTME was
not converted to laparotomy whilst surgery in five
patients undergoing LaTME was converted to laparo-
tomy (0.0% vs 10.4%, P = 0.056; Table 3). Reasons for
conversion were adhesions, obesity, bleeding and insuf-
ficient bowel length for stoma creation.
No statistically significant differences were observed
for hospital stay, anastomotic leakage, ileus, cardiopul-
monary complications, wound infections, Clavien–
Dindo classification, CCI, readmissions, reoperations
and mortality (Table 4). Readmissions were due to
anastomotic leakage, high output stoma, ileus, pancre-
atic pseudocyst and iatrogenic small bowel perforation.
The indications for reoperations were anastomotic leak-
age and replacement of diverting ileostomy. In the
LaTME group, one patient died 2 days after discharge
of an unknown reason as autopsy was not performed.
In the overall study population of 220 patients, mul-
tivariate penalized regression analyses showed that surgi-
cal approach is not associated with Clavien–Dindo
classification > II (OR 1.02, 95% CI 0.41–2.51,
P = 0.970), CCI (estimate 0.77, 95% CI 6.84 to
5.31, P = 0.805), readmission (OR 1.13, 95% CI 0.43–
2.99, P = 0.802) and reoperation (OR 1.33, 95% CI
0.49–3.64, P = 0.574; Table 5).
Discussion and conclusions
This propensity score matched study of a prospective
multicentre cohort study aimed to compare postopera-
tive morbidity between TaTME and LaTME. Our
Prospective cohort of patients 
undergoing partial or total mesorectal
resection N = 301  
Other indication than rectal carcinoma
N = 7  
- Crohn’s Disease
- Fistula 
- Mesh erosion
- Solitary rectal ulcer syndrome
- Gynaecological cancer
- Gastrointestinal stromal tumor (GIST)
- Neuroendocrine tumor (NET)
Partial mesorectal surgery or open
approach N = 74  
Transanal or laparoscoic total
mesorectal resection for rectal
carcinoma N = 220  
Figure 1 Flowchart of patient selection.
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results suggest that TaTME is a safe and feasible
approach for rectal cancer resection and has similar
postoperative morbidity to LaTME.
Nowadays, high conversion rates from laparoscopic
to open surgery are reported for rectal resection
especially in elderly patients and obese patients con-
tributing to postoperative morbidity [6]. Even in the
most recent clinical trials comparing laparoscopic vs
robotic assisted TME for rectal cancer, conversions were
up to 10% in both arms [19]. This is one of the main
Table 1 Demographic characteristics for patients undergoing LaTME and TaTME.
TaTME
119 (54.1%)
LaTME
101 (45.9%) Missing (%) P value
Baseline characteristics
Age, median (IQR), year 62.0 (56.0–67.0) 66.0 (59.5–73.0) 0 (0.0) 0.003
Gender
Male 86 (72.3%) 64 (63.4%) 0 (0.0) 0.158
Female 33 (27.7%) 37 (36.6%)
BMI, median (IQR), kg/m2 26.6 (23.7–29.7) 25.2 (23.2–28.7) 1 (0.5) 0.162
Smoking
Yes 15 (12.7%) 11 (11.5%) 6 (2.7) 0.780
No 103 (87.3%) 85 (88.5%)
Alcohol abuse
Yes 16 (13.6%) 11 (11.7%) 8 (3.6) 0.687
No 102 (86.4%) 83 (88.3%)
Bowel preparation
Yes 116 (97.5%) 82 (92.1%) 12 (5.5) 0.102*
No 3 (2.5%) 7 (7.9%)
Previous abdominal surgery
Yes 37 (31.1%) 35 (35.0%) 1 (0.5) 0.540
No 82 (68.9%) 65 (65.0%)
ASA score
I 11 (9.2%) 16 (16.0%) 1 (0.5) 0.355*
II 77 (64.7%) 64 (64.0%)
III 30 (25.2%) 19 (19.0%)
IV 1 (0.8%) 1 (1.0%)
Tumour distance to anal verge, median (IQR), cm 5.0 (2.1–10.0) 12.0 (9.0–15.0) 12 (5.5) < 0.001
pT stage
pT0 21 (17.8%) 6 (6.0%) 7 (3.1) 0.027*
pT1 16 (13.6%) 19 (19.0%)
pT2 36 (30.5%) 26 (26.0%)
pT3/4 42 (35.6%) 47 (47.0%)
pN stage
pN0 83 (69.7%) 68 (67.3%) 7 (3.1) 0.292
pN1 17 (14.3%) 22 (21.8%)
pN2 14 (11.8%) 8 (7.9%)
pN3 0 (0.0%) 1 (1.0%)
Neoadjuvant radiotherapy
Yes 67 (56.3%) 60 (60.0%) 1 (0.5) 0.581
Short-course 14 34
Long-course 47 25
No 52 (43.7%) 40 (40.0%)
Neoadjuvant chemotherapy
Yes 52 (43.7%) 28 (28.0%) 1 (0.5) 0.016
No 67 (56.3%) 72 (72.0%)
ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; LaTME, laparoscopic total mesorectal
excision; TaTME, transanal total mesorectal excision.
*Fisher’s exact test.
Bold values indicates P value <0.05.
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Table 2 Postmatching baseline characteristics.
TaTME
48
LaTME
48 Missing (%) P value
Age, median (IQR), year 65.0 (56.8–71.0) 64.0 (59.3–73.0) 0 (0.0) 0.752
Gender
Male 33 (68.8%) 32 (66.7%) 0.827
BMI, median (IQR), kg/m2 27.0 (24.5–30.7) 26.1 (24.0–29.0) 1 (1.0) 0.221
Smoking 5 (10.4%) 6 (12.5%) 5 (5.2) 0.661
Alcohol abuse 7 (14.6%) 2 (4.2%) 5 (5.2) 0.164*
ASA score
I 4 (8.3%) 6 (12.5%) 0 (0.0) 0.953*
II 29 (60.4%) 28 (58.3%)
III 14 (29.2%) 13 (27.1%)
IV 1 (2.1%) 1 (2.1%)
Tumour location, median (IQR), cm 10.0 (6.0–10.8) 9.5 (7.0–12.0) 0 (0.0) 0.459
Neoadjuvant radiotherapy 21 (43.8%) 31 (64.6%) 0 (0.0) 0.041
Short-course 5 (10.4%) 16 (33.3%)
Long-course 15 (31.3%) 14 (29.2%)
Neoadjuvant chemotherapy 14 (29.2%) 16 (33.3%) 0 (0.0) 0.660
pT stage
pT0 3 (6.3%) 2 (4.2%) 0 (0.0) 0.973*
pT1 7 (14.6%) 7 (14.6%)
pT2 15 (31.3%) 14 (29.2%)
pT3/4 23 (47.9%) 25 (52.1%)
pN stage
pN0 32 (66.7%) 34 (70.8%) 0 (0.0) 0.660
pN+ 16 (33.3%) 14 (29.2%)
ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; LaTME, laparoscopic total mesorectal
excision; TaTME, transanal total mesorectal excision.
*Fisher’s exact test.
Bold values indicates P value <0.05.
Table 3 Postmatching surgical characteristics.
TaTME
48
LaTME
48 Missing (%) P value
Duration of surgery, median (IQR), min 221.0 (187.50–263.50) 180.0 (141.0–205.0) 3 (3.1) < 0.001
Duration of anaesthesia, median (IQR), min 264.0 (228.8–313.3) 217.0 (176.5–244.3) 8 (8.3) < 0.001
Conversion 0 (0.0%) 5 (10.4%) 0 (0.0) 0.056*
Construction of anastomosis
Hand-sewn 7 (14.6%) 0 (0.0%) 0 (0.0) 0.012*
Stapler 41 (85.4%) 48 (100.0%)
Configuration of anastomosis
Side-to-end 26 (54.2%) 41 (85.4%) 3 (3.1) < 0.001*
End-to-end 20 (41.7%) 4 (8.3%)
End-to-side 0 (0.0%) 2 (4.2%)
Diverting ileostomy 40 (83.3%) 23 (47.9%) 0 (0.0) < 0.001
CRM involvement 2 (4.2%) 1 (2.1%) 10 (10.4) 1.000*
DRM involvement 5 (10.4%) 8 (16.7%) 8 (8.3) 0.322
CRM, circumferential resection margin; DRM, distal resection margin; IQR, interquartile range; LaTME, laparoscopic total
mesorectal excision; TaTME, transanal total mesorectal excision.
*Fisher’s exact test.
Bold values indicates P value <0.05.
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drawbacks of conventional laparoscopic surgery for rec-
tal resection. In the present study, TaTME was not
converted at all whilst LaTME was converted to laparo-
tomy in 10.4% of cases. A recent single-centre case-
matched study reported similar results [20]. This low
incidence of conversion seems to be the main advan-
tages of this new technique.
With the introduction of minimally invasive tech-
niques, the short-term outcomes of rectal surgery have
improved over recent decades. Despite these advances,
the incidence of anastomotic leakage has not been
reduced [21]. Anastomotic leakage is one of the major
concerns after rectal resection because of associated mor-
bidity and mortality. A recent study demonstrated that
large rectal tumours in obese, diabetic male patients who
smoke have the highest risk for anastomotic leakage after
TaTME [22]. In line with previous literature, we found
no difference in leakage rate for TaTME and LaTME
Table 4 Postmatching postoperative course comparison.
TaTME
48
LaTME
48 Missing (%) P value
Hospital stay, median (IQR), days 8.0 (6.0–13.5) 7.5 (5.0–13.8) 0 (0.0) 0.596
Anastomotic leakage 10 (20.8%) 9 (18.8%) 0 (0.0) 0.798
Ileus 7 (14.6%) 8 (16.7%) 0 (0.0) 0.779
Cardiopulmonary complications 0 (0.0%) 3 (6.3%) 0 (0.0) 0.242*
Wound infection 2 (4.2%) 1 (2.1%) 0 (0.0) 1.000*
Clavien–Dindo classification > II 9 (18.8%) 10 (20.8%) 0 (0.0) 0.798
Comprehensive complication index, median (IQR) 14.8 (0.0–22.6) 4.4 (0.0–22.6) 0 (0.0) 0.602
Readmission 10 (20.8%) 5 (10.4%) 0 (0.0) 0.160
Reoperation 8 (16.7%) 7 (14.6%) 0 (0.0) 0.779
Mortality 0 (0.0%) 1 (2.1%) 0 (0.0) 1.000*
IQR, interquartile range; LaTME, laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision.
*Fisher’s exact test.
Table 5 Multivariate penalized logistic regression to test the association between approach and Clavien–Dindo > II, readmission
and reoperation.
Clavien–Dindo > II CCI Readmission Reoperation
OR
95% CI P value
Estimate
95% CI P value
OR
95% CI P value
OR
95% CI P value
Age, median (IQR), years 0.96
0.92–0.99
0.014 0.32
0.55 to 0.08
0.008 0.97
0.94–1.01
0.181 0.96
0.92–1.00
0.032
Gender 0.77
0.37–1.59
0.482 0.76
5.66 to 4.14
0.760 0.88
0.39–2.02
0.770 1.01
0.44–2.31
0.980
BMI, median (IQR), kg/m2 0.98
0.90–1.06
0.550 0.06
0.45 to 0.57
0.820 0.98
0.89–1.07
0.618 1.03
0.94–1.12
0.588
Location lesion, median (IQR), cm 1.00
0.92–1.08
0.990 0.23
0.32 to 0.78
0.417 1.06
0.97–1.16
0.171 0.96
0.87–1.05
0.385
pT 0.88
0.62–1.24
0.455 0.76
3.03 to 1.51
0.514 0.94
0.64–1.39
0.774 1.01
0.68–1.50
0.952
Neoadjuvant radiotherapy 0.97
0.41–2.26
0.939 1.63
4.21 to 7.47
0.585 1.05
0.41–2.70
0.920 0.86
0.34–2.16
0.748
Neoadjuvant chemotherapy 0.67
0.26–1.68
0.391 7.09
13.30 to 0.88
0.026 0.80
0.30–2.16
0.664 0.45
0.15–1.34
0.153
Diverting ileostomy 0.56
0.26–1.23
0.151 1.12
4.19 to 6.43
0.680 2.22
0.84–5.83
0.107 0.41
0.17–1.01
0.054
Approach 1.02
0.41–2.51
0.970 0.77
6.84 to 5.31
0.805 1.13
0.43–2.99
0.802 1.33
0.49–3.64
0.574
BMI, body mass index; CCI, comprehensive complication index; IQR, interquartile range.
Bold values indicates P value <0.05.
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[9–11,13,23–25]. Therefore, the transanal approach
does not seem to reduce the incidence of anastomotic
leakage after rectal cancer resection.
In contrast to previous studies, our results show that
TaTME is associated with more prolonged surgery and
anaesthesia [7,8]. Previously, it was suggested that
TaTME can be performed by two teams simultaneously;
however, not all hospitals have the capacity to perform
TaTME in two teams due to lack of personnel. When
TaTME is not performed with two teams simultane-
ously, this may result in prolonged duration of surgery
and anaesthesia. Moreover, this study included hospitals
in which the TaTME technique was recently intro-
duced. Therefore, a longer duration of surgery might
reflect a learning curve [26]. In addition, creation of a
diverting ileostomy, which was more often performed in
the TaTME group, may also influence duration of sur-
gery and anaesthesia.
After matching for propensity score, patients who
underwent LaTME received neoadjuvant radiotherapy
more frequently than TaTME patients. The ESMO clin-
ical practice guidelines have recently been updated indi-
cating that specific patients with intermediate risk rectal
cancer do not need neoadjuvant treatment in order to
minimize local recurrence if good quality TME can be
achieved [27]. Since TaTME has recently become more
popular, this difference might mirror the update of
these guidelines. In addition, this study showed, in the
unmatched cohort, that preoperative radiotherapy was
not associated with postoperative morbidity (Table 5),
and therefore it is unlikely that this difference in base-
line characteristics has influenced the results.
In the postmatching TaTME group, more manual
and end-to-end anastomoses were observed, even
though there were no baseline differences between the
two groups on tumour height. A systematic review
showed similar results [28].
Diverting ileostomies are common after rectal resec-
tion but do not reduce anastomotic leakage or mortality
[29]. In fact, diverting ileostomies tend to mitigate the
consequences of anastomotic leakage resulting in less
invasive treatment strategies. In the present study,
patients who underwent TaTME were more often
diverted during primary surgery. A recent single-centre
case-matched study found similar results [25]. This dif-
ference might reflect surgeons’ perception to protect
the anastomosis following the new approach whilst this
risk is unsubstantiated.
In the present study, tumour location was derived
from endoscopy. There seems to be a significant differ-
ence between the tumour location of colorectal cancers
reported by endoscopy and the actual location deter-
mined during surgery [30]. Moreover, the anal verge
was the reference for determination of the tumour loca-
tion. Thus, this distance includes the anal canal of 3–
5 cm [31]. This may explain the relatively high tumour
location in both the TaTME and the LaTME groups.
Functional outcomes are of interest for future
research. TaTME possibly provides better visualization
of the distal rectum which may contribute to preserva-
tion of pelvic nerves and vascularity resulting in better
urinary and sexual function [23,32].
At this moment, this subgroup analysis provides the
highest level of evidence on postoperative short-term
results after TaTME and LaTME currently available
since the results are based on a multicentre prospective
cohort study. Nevertheless, we recognize several limita-
tions of the study. First, the TME procedures in both
groups were not standardized so different types of
laparoscopic assisting techniques (i.e. single-port or
multi-port) were used. Second, cohort studies are sensi-
tive to bias and confounding. Nevertheless, both
propensity score analysis and penalized multivariate
regression analyses were performed to adjust for con-
founding effects showing similar results.
This propensity score matched study of a prospective
multicentre cohort study aimed to compare postopera-
tive morbidity between TaTME and LaTME. It was
shown that TaTME is a safe and feasible approach for
rectal cancer resection. This new technique obtained
similar postoperative morbidity. This study is the first to
provide evidence based upon prospective data. How-
ever, oncological safety in terms of CRM involvement
and local recurrence should be obtained in a well-
designed randomized controlled trial.
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